Truist Financial Boosts Glaukos (NYSE:GKOS) Price Target to $152.00

Glaukos (NYSE:GKOS) had its price target upped by Truist Financial from $145.00 to $152.00 in a research report report published on Monday, Benzinga reports. Truist Financial currently has a buy rating on the medical instruments supplier’s stock.

Several other brokerages also recently issued reports on GKOS. Wells Fargo & Company lifted their target price on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Stifel Nicolaus boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. Morgan Stanley boosted their price target on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, BTIG Research raised their price objective on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $130.45.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $128.20 on Monday. The stock has a market cap of $6.46 billion, a PE ratio of -44.51 and a beta of 1.02. Glaukos has a 1 year low of $59.22 and a 1 year high of $136.60. The firm has a fifty day moving average price of $127.66 and a 200-day moving average price of $116.47. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The company had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. Glaukos’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.55) EPS. Equities analysts anticipate that Glaukos will post -2.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $13,216,581.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,250 shares of company stock worth $4,825,873 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its position in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after acquiring an additional 486 shares during the last quarter. Caldwell Sutter Capital Inc. boosted its stake in shares of Glaukos by 5,860.0% during the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 1,465 shares during the period. Fifth Third Wealth Advisors LLC bought a new position in shares of Glaukos in the second quarter worth about $187,000. Procyon Advisors LLC purchased a new position in Glaukos in the 3rd quarter worth about $210,000. Finally, Brighton Jones LLC bought a new stake in Glaukos during the 2nd quarter valued at about $208,000. 99.04% of the stock is owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.